Intercept Pharmaceuticals Receives $30,000,000 Series C Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6e85fb7e-c6db-4324-9e81-8f00964b6842&Preview=1
Date
8/13/2012
Company Name
Intercept Pharmaceuticals
Mailing Address
18 Desbrosses Street New York, NY 10013
Company Description
Intercept Pharmaceuticals Inc., is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Website
http://www.interceptpharma.com
Transaction Type
Venture Equity
Transaction Amount
$30,000,000
Transaction Round
Series C
Proceeds Purposes
This financing allows us to continue advancing our lead compound OCA in POISE, our Phase 3 PBC trial, while pursuing other therapeutic indications of interest.
M&A Terms
Venture Investor
OrbiMed Advisors
Venture Investor
OrbiMed Advisors
Venture Investor
Genextra S.p.A.
Venture Investor
Undisclosed